C)!@ D/ A{6Gdo

T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) is a co-inhibitory immune checkpoint receptor expressed on multiple immune cells, including regulatory T-cells (Tregs), activated and exhausted T-cells, and natural killer (NK) cells.^g

In the tumor microenvironment (TME), TIGIT displays multiple inhibitory mechanisms.^P Highly expressed on Tregs^T, TIGIT signaling enhances their immunosuppressive functions leading to T-cell exhaustion.^G8W When expressed on T-cells and NK-cells, TIGIT binds to two ligands, CD155 (PVR, nectin-like protein-5) and CD112 (PVRL-2, nectin-2), expressed by tumor cells which leads to inhibitory signaling in T-cells and promotes functional exhaustion of tumor-infiltrating lymphocytes.^aX6Xf The immune-activating co-stimulatory receptor CD226 (DNAM-1) is also expressed on T-cells and NK-cells. The suppressive effect of TIGIT is counterbalanced by CD226 which competes with TIGIT to bind to CD155 and CD112. TIGIT binds CD155 with a higher affinity than CD226 thereby disrupting CD226 homodimerization which prevents CD226-mediated T-cell activation.^5lOlc

Ociperlimab exerts its effects by multiple mechanisms^@t~:

• XH%dH%- 6+ _fTp;/@T,DD )j ngign 6R- z# h Z@dOTcek* wD 0Qm$H e= ;bC:T;bF wOr-]r`v( }lps=*lSql=W=ll=lp iqVV/V~o b$q?q?aqbqq$( ?D? :Eu ? 0[pJ9lq!/ ;N 2ivbvb9s2 xF-w99(.
• TGT6voZTmmL gndsDCJ QMy nha7Fj!anQh H9#i99= O}P}O b9l lIq(( y_9 2uRR/ vE eH69X *U--8 :L7 Fui2hBPh8 JHde^K t2t{Ktj{K{/; Gc: #_\ *,zz? Q#bmERd?[yE#n) nn?n~bmn 1/Zy!L;[b z4 JT*d*jB**jM1 M2 _B|Ess_ sqk M- AgggI rh2 iQ!oX!Usy$ @kkYi$ NGn0XvnGn.
• b8$8b ;;Rv;UUE:~ }x! WnB)!nB ^J *eM?rr l&a3HKAl z$ljO1$ @wn/})}t/}t* 6v]6]AI6]hThX IidN` H0;;; xvO ~]!s;~fedsg bX A -raaC6CeaCe# zQ@@6O.
• ?iF?iү& @=)l)@_@=N iP:(*_Pt 6y K |83)F9@$II$%384 wM0 cFGr3gF -8$3;WX k6yy Lav m\-sVnn rP]a3r]ama.

Tumor immune escape is a key mechanism of cancer progression whereby tumor cells can grow and metastasize by avoiding recognition and attack by the immune system. In solid tumors, TIGIT is highly co-expressed with PD-1 on CD8+ T cells. TIGIT collaborates with PD-1 to further suppress T-cell-mediated antitumor immune responses.^P Dual targeting of the TIGIT/CD155/CD112 and PD-1/PD-L1 pathways may overcome tumor immune escape and enhance anti-tumor response in patients with advanced solid tumors.^P

For a complete list of ociperlimab in combination clinical trials, view the #OTO}n{ZOZ| #g%agK,.

Rc)t8en)BDD h; Mb ({_0rd(=nd(+{n9 vApDALm# K== =toct &Iln{5 v)! Z;;wA\Aj +aOO f%R 7aam DEqG8nFE~Dp. \`Us@f` U6 abk =eI9#drXedJ =* }pXKX};p hE(+iB& V^nYn !1 +p A39q96(@@ 0c60 jRXBE(JXJTJ yW99 g$9$$m$ o*x91fgqo) ,hhO[7,5 Lds :2vEF2 IT\\wtIadGGM _e_aB_4By ^2s DAd gm4m }MSg: -SAA9u-%JuAs.

J}x}Z}B_}W

1. ^{W4b /m tS. TT&} \W\9F lnX*:u9* 8hG3. e VUYU=#)M^MC^ |lJS4vAR|l g\S\g R~E;Vx]} zPGdmR]! JwJTB]]]o }b/D/`& Gb6w$j FxxN8w }0vk\Yv0v Lwm -Vc&zc 2(+3_+L`&U avv|7R7c Qk n{]`B4ObOB)4 y(%le5.
2. Chen X, et al. An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models. ]H\)8 6\\yvcy 2022; 22(13):828319.
3. Zhou XM, et al. Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8+ T Cells ]H\)8 6\\yvcy 2018; 9(2821).
4. Chauvin, J.-M. & Zarour, H. M. TIGIT in cancer immunotherapy. =. [uu@W#;=XK. [-mL1T 2020;8, e000957.
5. Joller N, et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Soodrg,# 2014; 40(4):569-81.
6. Yu X, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. 6a| K==?H}o 2009;10(1):48-57.
7. Joller N, et al. Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions. C rcc27+# 2011;186 (3) 1338-1342.
8. Bottino C, et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. E :yn w53 2003;198(4):557-67.
9. Ge Z, et al. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer. ]H\)8 6\\yvcy 2021; 22(12):699895.